Nxera Pharma Co., Ltd. (OTCMKTS:SOLTF – Get Free Report) crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $6.11 and traded as high as $7.3140. Nxera Pharma shares last traded at $7.3140, with a volume of 100 shares.
Nxera Pharma Price Performance
The stock’s 50-day simple moving average is $6.18 and its 200 day simple moving average is $5.68.
Nxera Pharma Company Profile
Nxera Pharma Co, Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company’s development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders.
Featured Stories
- Five stocks we like better than Nxera Pharma
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for Nxera Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nxera Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
